AC Immune reports positive interim Phase 1 data for NLRP3 inhibitor ACI-19764

ACIU•2026-08-20

Next steps and timeline

Development focus now shifts to a Phase 1b cohort in cardiovascular-risk patients to gauge anti-inflammatory activity; initial results are expected by year end.

Full Phase 1/1b results are slated for H1 2027, setting the timeline for next-stage clinical and partnering decisions.

Positive interim Phase 1 results for ACI-19764

AC Immune reported positive preliminary Phase 1 results for ACI-19764, an oral NLRP3 inhibitor, with results already presented as interim data.

Early readout showed the drug was safe and well tolerated, with evidence it reached the central nervous system.

AC Immune reports positive interim Phase 1 data for NLRP3 inhibitor ACI-19764

Next steps and timeline

Positive interim Phase 1 results for ACI-19764

Related News

Array Technologies plans shift beyond solar trackers into integrated balance-of-system platform

NovaBridge net loss widens to $37.9 million in FY26 first half; R&D expenses more than doubled to $14.3 million

Target Corp <TGT.N>: Truist Securities Raises Target Price to $167 from $147

Castle Biosciences to present at Baird Global Healthcare Conference

Novonesis expects results from weight-loss drug supplement study in 2027